CSL Debt/Equity Ratio 2017-2024 | CSLLY

CSL debt/equity ratio for the quarter ending June 30, 2024 was 0.58.

  • CSL average debt/equity ratio for 2023 was 0.6, a 25% decline from 2022.
  • CSL average debt/equity ratio for 2022 was 0.48, a 5.88% increase from 2021.
  • CSL average debt/equity ratio for 2021 was 0.51, a 36.25% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

CSL Debt/Equity Ratio 2017-2024 | CSLLY

  • CSL average debt/equity ratio for 2023 was 0.6, a 25% decline from 2022.
  • CSL average debt/equity ratio for 2022 was 0.48, a 5.88% increase from 2021.
  • CSL average debt/equity ratio for 2021 was 0.51, a 36.25% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173B
Vertex Pharmaceuticals (VRTX)$127.1B
Gilead Sciences (GILD)$114.2B
Bristol Myers Squibb (BMY)$112.1B
Regeneron Pharmaceuticals (REGN)$89.7B
GSK (GSK)$74.4B
Argenex SE (ARGX)$35.2B
Alnylam Pharmaceuticals (ALNY)$35.2B
Biogen (BIIB)$25.4B
BioNTech SE (BNTX)$25.4B
Illumina (ILMN)$24.2B
Moderna (MRNA)$19.9B
BeiGene (BGNE)$19.7B
Incyte (INCY)$15.6B
Genmab (GMAB)$14.8B
Insmed (INSM)$13B
Vaxcyte (PCVX)$13B
BioMarin Pharmaceutical (BMRN)$12.6B
Sarepta Therapeutics (SRPT)$12.2B
Bio-Techne Corp (TECH)$12B
Exelixis (EXEL)$10.1B
Exact Sciences (EXAS)$10.1B
QIAGEN (QGEN)$10B
Revolution Medicines (RVMD)$9.9B
Intra-Cellular Therapies (ITCI)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$8.2B
Ascendis Pharma (ASND)$7.8B
Halozyme Therapeutics (HALO)$7.7B